Aarti Pharmalabs Limited reports Q1 FY 2026-27 results and approves director role changes
Aarti Pharmalabs · Pharmaceuticals & Biotechnology
Key highlights
- Q1 standalone revenue from operations: ₹534.59 crore; net profit: ₹71.31 crore; EPS: ₹7.87 (basic)
- Board approved change of Shri Rashesh C. Gogri as Managing Director and Smt. Hetal Gogri Gala as Executive Director effective October 1, 2026, subject to shareholder approval
- Proposed capacity addition of 405 KL in new block with investment of ₹149 crore financed by internal accruals and borrowings
Why it's rated major development: the year-on-year change is 65% (50% or more)
Figures checked against the filing by a second AI read. About the business, not the share price.
Original filing
Board Meeting Outcome for Outcome Of Board Meeting Held On August 07, 2026.
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Aarti Pharmalabs
- Financial resultsMajor developmentAarti Pharmalabs approves Sept 2026 results; CFO Piyush Lakhani resigns
- Board / shareholder meeting outcomeNotableAarti Pharmalabs Limited announces results of 7th AGM held on September 22, 2026
- Financial resultsMajor developmentAarti Pharmalabs Ltd announces Q1 FY 2026-27 results and role changes in management
- Capex / expansionMajor developmentAarti Pharmalabs reports quarter ended June 30, 2026 results; approves Rs.149 Crores capex
- Capex / expansionNotableAarti Pharmalabs inaugurates new manufacturing block at Tarapur to expand capacity
Other capex / expansion filings this fortnight
- Maharaja & Speedex India Limited raises manufacturing capacity to 72 lakh units/year
- Elin Electronics Q2 FY27 earnings report with 10% revenue growth and margin update
- HOAC Foods India Limited H1 FY27 Earnings Call Transcript dated November 5, 2026
- Gujarat State Fertilizers & Chemicals Limited Q2 FY27 Earnings Call Highlights
- Supriya Lifescience H1 revenue up 14.8% to ₹396.04 crore; Q2 profit falls
- V-MARC India Ltd announces Q2 & H1 FY27 unaudited financial results and review report
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.